In the second segment of this roundtable series, the panel discusses the importance of safe sampling in biomarker testing.
In the first segment of this roundtable series, the panel discusses the initial steps in NSCLC diagnosis and treatment.
The efficacy of zongertinib was evaluated in Beamion LUNG-1, an open-label, multicenter, multi-cohort trial.
In the seventh part of this roundtable series, the panel discusses surgical preparations and considerations.
In the sixth segment of this roundtable series, the discusses how multidisciplinary teams monitor and manage AEs.
In the fifth segment of the roundtable series, experts discuss advances in adjuvant, neoadjuvant and perioperative treatment.
In the fourth segment of this roundtable discussion, the panel shares navigation strategies for patients with NSCLC.
In the third part of this roundtable discussion, experts share insights on the decision-making process surrounding treatment
Dr. Osarogiagbon discussed the impact of the lung cancer screening program on diagnosis rates across the Mississippi Delta.
In the second segment of this roundtable discussion, experts discuss considerations surrounding biospies and biomarkers.